Lee Danner & Bass Inc. increased its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 32.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,185 shares of the company's stock after purchasing an additional 8,870 shares during the quarter. Lee Danner & Bass Inc.'s holdings in Henry Schein were worth $2,478,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its position in shares of Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after acquiring an additional 143 shares in the last quarter. Guggenheim Capital LLC boosted its position in shares of Henry Schein by 2.5% during the 4th quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after acquiring an additional 159 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Henry Schein by 23.2% during the 1st quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after acquiring an additional 201 shares in the last quarter. Humankind Investments LLC boosted its position in shares of Henry Schein by 7.4% during the 4th quarter. Humankind Investments LLC now owns 3,057 shares of the company's stock worth $212,000 after acquiring an additional 211 shares in the last quarter. Finally, J. Safra Sarasin Holding AG boosted its position in shares of Henry Schein by 1.1% during the 4th quarter. J. Safra Sarasin Holding AG now owns 22,098 shares of the company's stock worth $1,529,000 after acquiring an additional 231 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
HSIC has been the subject of several analyst reports. Barrington Research lowered their price objective on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company decreased their target price on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Wall Street Zen downgraded Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, Piper Sandler reduced their price objective on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $79.30.
View Our Latest Report on HSIC
Henry Schein Price Performance
Shares of HSIC traded up $0.31 on Tuesday, reaching $73.76. The stock had a trading volume of 529,553 shares, compared to its average volume of 1,716,460. The firm has a market capitalization of $8.98 billion, a PE ratio of 23.05, a PEG ratio of 2.41 and a beta of 0.87. The company has a quick ratio of 0.75, a current ratio of 1.38 and a debt-to-equity ratio of 0.50. The firm has a 50-day moving average of $70.86 and a 200 day moving average of $71.23. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. The business had revenue of $3.17 billion for the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 14.87% and a net margin of 3.21%. The company's revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.10 EPS. Sell-side analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.
About Henry Schein
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.